CTRI/2015/07/006065已完成3 期
A Multi Centric, Randomized, Assessor Blind, Parallel, Phase III Study to Evaluate Clinical Efficacy, Safety and Pharmacokinetics of Intas Denosumab (60 mg Single Use Vial) in Comparison to The Reference Listed Drug Prolia® (Denosumab, 60 mg Single Use Vial) in Women With Postmenopausal Osteoporosis. - NA
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 114
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Ambulatory woman <=80 years of age.
- •2. Bone Mineral Density: The subject having a BMD absolute value consistent with a T-score between -2.5 to -4 at either the lumbar spine or total hip.
- •3. Patients able to understand and voluntarily provide written informed consent before screening, following an explanation of the nature and purpose of this study.
排除标准
- •1. History of any metabolic bone disease, e.g., osteomalacia or osteogenesis imperfecta, which may interfere with the interpretation of the findings, Pagetâ??s disease, Cushingâ??s disease or Hyperprolactinemia
- •2. Current hyperparathyroidism or hypoparathyroidism
- •3. History of uncontrolled Hyper- or hypothyroidism except subjects on stable thyroid hormone replacement therapy for last one year
- •4. History of Rheumatoid arthritis
- •5. History of malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical or breast ductal carcinoma in situ) within the last 5-years.
- •6. History of Cirrhosis of the liver or Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbertâ??s syndrome or asymptomatic gallstones).
- •7. History of Drug or alcohol abuse: Evidence of alcohol or substance-abuse within the last 12-months which the Investigator believes would interfere with understanding or completing the study.
- •8. Any physical or psychiatric disorder that compromises the ability of the subject to give written informed consent or to comply with study procedures.
- •9. Known to have tested positive for human immunodeficiency virus (HIV), HCV or HBsAg.
- •10. Any of the following Oral/Dental Conditions
- •a. Prior history or current evidence of osteomyelitis or osteonecrosis of the jaw.
- •b. Active dental or jaw condition which requires oral surgery.
- •c. Planned invasive dental procedure.
- •d. Non-healed dental or oral surgery.
研究者
相似试验
尚未招募
3 期
Efficacy and Safety of Lumateperone in Comparison to Quetiapine for the Treatment of Bipolar II DepressioCTRI/2023/10/058583Sun Pharma Laboratories Limited SP
尚未招募
3 期
Evaluate the Efficacy and Safety of Pimavanserin in Comparison to Quetiapine for the Treatment of Hallucinations (experience of seeing something that is not really there) and Delusions (a false belief) Associated with Parkinson’s Disease PsychosisCTRI/2022/04/041968Sun Pharma Laboratories Limited
已完成
4 期
Phlogam and Disperzyme use for reducing pain and swelling after small surgeryCTRI/2017/12/010804Aksigen Hospital Care309
招募中
3 期
Bioequivalence study of Estradiol 10μg tablet and Vagifem® 10μg tablet in healthy postmenopausal women with symptoms of vulvar and vaginal atrophy and no contraindication to estrogen therapy.CTRI/2014/05/004586Famy Care Ltd465
招募中
2 期
A clinical trial to compare the effects of coded Unani research drug UNIM-221 with allopathic drug Metformin in patients with Diabetes Mellitus Type IICTRI/2013/10/004092Central Council for Research in Unani Medicine CCRUM New Delhi624